Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Amylyx Pharmaceuticals

AMLX

----

OverviewOverview NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

Weekly Recap | MOAT.US -0.89%, lighter-volume pullback
Weekly Review·11 hours ago
MOAT-0.65%
Weekly Recap | ARKG.US +13.35%, AI healthcare leads genomics theme
Weekly Review·11 hours ago
ARKG+0.10%
Weekly Recap | Twist Bioscience +31.26%, signs deal with Lilly TuneLab
Weekly Review·12 hours ago
TWST+7.35%
Weekly Recap | RXRX.US +19.69%, most brokers rate it buy
Weekly Review·12 hours ago
RXRX+8.19%
Weekly Recap | Novavax +7.32%, outperforming the S&P 500
Weekly Review·12 hours ago
NVAX+1.10%
Weekly Recap | Medicinova +83.43%, most brokers rate it buy
Weekly Review·12 hours ago
MNOV-3.77%
Weekly Recap | LABU.US +0.73%, biotech ends mixed
Weekly Review·12 hours ago
Weekly Recap | ARQT.US +6.26%, consensus target above spot
Weekly Review·13 hours ago
ARQT-4.08%
Weekly Recap | Alnylam Pharma -3.67%, consensus target above spot
Weekly Review·13 hours ago
ALNY-2.42%
Weekly Recap | Abbvie +2.66%, closing in on record highs
Weekly Review·13 hours ago
ABBV-0.02%
Weekly Recap | SPDR S&P Biotech +0.33%, mixed biotech tape
Weekly Review·14 hours ago
XBI-0.97%
Weekly Recap | AMLX.US +78.73%, Phase 3 win sparks rally
Weekly Review·Aug 22 at 06:56 AM
AMLX-4.51%